Literature DB >> 35939163

Risk scores for Kawasaki disease, a management tool developed by the KAWA-RACE cohort.

Carlos D Grasa1,2,3, Elisa Fernández-Cooke4,5,6, Sara Domínguez-Rodríguez7,8, Javier Aracil-Santos1, Ana Barrios Tascon9, Judith Sánchez-Manubens10,11, Beatriz Mercader12, Jordi Antón10, Esmeralda Nuñez13, Enrique Villalobos14, Matilde Bustillo15, Marisol Camacho16, Manuel Oltra Benavent17, Gemma Giralt18, Ana Maria Bello Naranjo19, Beatriz Rocandio20, Cristina Calvo1,2,3,21.   

Abstract

INTRODUCTION/
OBJECTIVES: Asian scores developed to predict unresponsiveness to intravenous immunoglobulin (IVIG) or development of coronary artery aneurysms (CAA) in patients with Kawasaki disease (KD) are not appropriate in Western populations. The purpose of this study is to develop 2 scores, to predict unresponsiveness to IVIG and development of CAA, appropriate for Spanish population.
METHOD: Data of 625 Spanish children with KD collected retrospectively (2011-2016) were used to identify variables to develop the 2 scores of interest: unresponsiveness to IVIG and development of CAA. A statistical model selected best variables to create the scores, and scores were validated with data from 98 patients collected prospectively.
RESULTS: From 625 patients of the retrospective cohort, final analysis was performed in 439 subjects: 37 developed CAA, and 212 were unresponsive to IVIG. For the score to predict CAA, a cutoff ≥ 8 was considered for high risk, considering a score system with a different weight for each of the eight variables. External validation showed a sensitivity of 22% and a specificity of 75%. The score to predict unresponsiveness to IVIG established a cutoff ≥ 8 for high risk, considering a score system with a different weight for each of the nine variables. External validation showed a sensitivity of 78% and a specificity of 50%.
CONCLUSIONS: Two risk scores for KD were developed from Spanish population, to predict development of CAA and unresponsiveness to IVIG; validation in other cohorts could help to implement these tools in the management of KD in other Western populations.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Coronary artery aneurysm; Kawasaki disease; Score; Unresponsiveness IVIG

Year:  2022        PMID: 35939163     DOI: 10.1007/s10067-022-06319-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  19 in total

1.  Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease.

Authors:  Masaaki Mori; Takako Miyamae; Tomoyuki Imagawa; Shigeki Katakura; Kazuhiro Kimura; Shumpei Yokota
Journal:  Mod Rheumatol       Date:  2004       Impact factor: 3.023

2.  Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.

Authors:  Tohru Kobayashi; Yoshinari Inoue; Kazuo Takeuchi; Yasunori Okada; Kazushi Tamura; Takeshi Tomomasa; Tomio Kobayashi; Akihiro Morikawa
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

3.  Kawasaki disease: a prospective population survey in the UK and Ireland from 2013 to 2015.

Authors:  Robert M R Tulloh; Richard Mayon-White; Anthony Harnden; Athimalaipet V Ramanan; E Jane Tizard; Delane Shingadia; Colin A Michie; Richard M Lynn; Michael Levin; Orla D Franklin; Pippa Craggs; Sue Davidson; Rebecca Stirzaker; Mike Danson; Paul A Brogan
Journal:  Arch Dis Child       Date:  2018-08-13       Impact factor: 3.791

4.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.

Authors:  Tetsuya Sano; Shunji Kurotobi; Kouji Matsuzaki; Takehisa Yamamoto; Ichiro Maki; Kazunori Miki; Shigetoyo Kogaki; Junichi Hara
Journal:  Eur J Pediatr       Date:  2006-08-01       Impact factor: 3.183

5.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

6.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

7.  Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: The Nationwide Survey in Japan, 2017-2018.

Authors:  Ryusuke Ae; Nobuko Makino; Koki Kosami; Masanari Kuwabara; Yuri Matsubara; Yosikazu Nakamura
Journal:  J Pediatr       Date:  2020-05-23       Impact factor: 4.406

8.  Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance.

Authors:  Lynn A Sleeper; L Luann Minich; Brian M McCrindle; Jennifer S Li; Wilbert Mason; Steven D Colan; Andrew M Atz; Beth F Printz; Annette Baker; Victoria L Vetter; Jane W Newburger
Journal:  J Pediatr       Date:  2010-12-18       Impact factor: 4.406

Review 9.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Authors:  Brian W McCrindle; Anne H Rowley; Jane W Newburger; Jane C Burns; Anne F Bolger; Michael Gewitz; Annette L Baker; Mary Anne Jackson; Masato Takahashi; Pinak B Shah; Tohru Kobayashi; Mei-Hwan Wu; Tsutomu T Saji; Elfriede Pahl
Journal:  Circulation       Date:  2017-03-29       Impact factor: 29.690

10.  Predicting IVIG resistance in UK Kawasaki disease.

Authors:  Sarah Davies; Natalina Sutton; Sarah Blackstock; Stuart Gormley; Clive J Hoggart; Michael Levin; Jethro A Herberg
Journal:  Arch Dis Child       Date:  2015-02-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.